Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Qiagen (QGEN) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $527.94 million, representing a surprise of +1.35%. The company delivered an EPS surprise of +3.33%, with the consensus EPS estimate being $0.60.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

• Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus the four-analyst average estimate of $36.58 million. The reported number represents a year-over-year change of -5.9%.
• Sales by Product Groups- Diagnostic solutions- QuantiFERON: $131 million versus $127.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.
• Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the three-analyst average estimate of $29.5 million. The reported number represents a year-over-year change of 0%.
• Sales by Product Groups- Other: $15 million versus $14.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change.
• Sales by Product Groups- PCR / Nucleic acid amplification: $74 million versus $69.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
• Sales by Product Groups- Genomics / NGS: $61 million versus $59.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.
• Sales by Product Groups- Diagnostic solutions: $204 million versus the three-analyst average estimate of $202.46 million. The reported number represents a year-over-year change of -1%.
• Sales by Product Groups- Sample technologies: $182 million compared to the $181.19 million average estimate based on three analysts. The reported number represents a change of +9.6% year over year.

View all Key Company Metrics for Qiagen here>>>

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research